Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 3)

Link copied
Case Copied 82 min read

FEDERAL COURT OF AUSTRALIA

Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 3) [2025] FCA 1179   

File number(s): NSD 698 of 2024
Judgment of: JACKMAN J
Date of judgment: 24 September 2025
Catchwords:

PATENTS – application for revocation of certain claims of patent on basis that claims are neither novel nor involve inventive step within meaning of s 18(1)(b) of the Patents Act 1990 (Cth) (Patents Act) when compared to prior art base – cross-claim for infringement of patent – where specification is a pour-on anthelmintic formulation for cattle involving a selected levamisole active ingredient and a macrocyclic lactone dissolved in a non-aqueous system that is stable – where prior art base existed before priority date – where expert witness relies on greater knowledge than common general knowledge (CGK) attributable to a person skilled in the art (PSA)

PATENTS – whether claims of patent lack inventive step – legal principles concerning prior art base, common general knowledge and obviousness considered – where expert witnesses required to undertake task of developing anthelmintic, using knowledge as at priority date – where applicant’s expert evidence does not reflect position of PSA – where comparison of other similar patents – inventive step found

PATENTS – whether claims of patent lack novelty – whether necessary to consider a notional set of claims, in valid form, which would be fairly based, as set out in Du Pont (defined in reasons) – where language of Patents Act does not require Court to determine hypothetical validity of notional claim – where notional claim requirement adds unnecessary complexity which was not intended by legislature – notional claim requirement is unnecessary – comparison of prior art document with patent in suit undertaken, claim by claim – each of contested claims held to be novel

HIGH COURT AND FEDERAL COURT – decision whether or not to follow previous judge’s decision should not be based on ‘judicial comity’ – where compelling reason to depart from previous judge

EVIDENCE – whether a Ferrcom inference (as defined in reasons) can apply to expert evidence – where difficulty determining whether there has been ‘fear’ of evidence being given or whether the significance of the evidence was simply not appreciated when the evidence in chief was prepared much earlier – where features of contemporary practice require expert reports to declare that all appropriate inquiries have been made and no matters of significance omitted – where no room left to tactically seek to avoid subject matter – Ferrcom inference superseded

Legislation: Patents Act 1990 (Cth)
Cases cited:

Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd [2024] FCA 1488

Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; (2002) 212 CLR 411

Apple Inc v Samsung Electronics Co Ltd [2011] FCA 1164; (2011) 284 ALR 309

Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2025] FCAFC 131

Aristocrat Technologies Australia Pty Ltd v Global Gaming Supplies Pty Ltd [2009] FCA 1495; (2009) 84 IPR 222

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] FCA 1179
Decision Date

CaseChat Overview and Summary

Abbey Laboratories Pty Ltd sought to revoke certain claims of a patent held by Virbac (Australia) Pty Ltd, contending that the claims were neither novel nor involved an inventive step within the meaning of the Patents Act 1990 (Cth). Virbac cross-claimed for infringement of the patent. The central issue was whether the patent claims lacked novelty and an inventive step when compared to the prior art base. Additionally, the court had to consider whether the expert evidence should be subject to a Ferrcom inference and whether a notional set of claims needed to be considered for assessing novelty.

The court found that the expert evidence should not be subject to a Ferrcom inference as contemporary practice concerning expert evidence does not allow for a party to tactically avoid certain subject matter. The court also held that the requirement to consider a notional set of claims for assessing novelty was unnecessary and added complexity that was not intended by the legislature. The court compared the prior art documents with the patent in question, claim by claim, and found each of the contested claims to be novel. The court determined that the patent claims involved an inventive step, finding that the applicant's expert evidence did not reflect the position of a person skilled in the art.

The court concluded that Abbey's challenge to the claims in the patent had only limited success, revoking three claims but upholding the rest. Virbac was granted declarations, injunctions, and an inquiry into pecuniary remedies. Abbey was given a four-week period before the injunctions took effect to allow for an orderly wind-down. The court set a timetable for the parties to file affidavits and written submissions on the question of costs.

Orders

Orders of the court

4. From 22 October 2025, each Cross-Respondent, whether by itself, its directors, officers, servants or agents, or otherwise be restrained, from infringing each of claims 1 to 10, 13, 15, 16 and 18 of the Patent, including by engaging in any of the following acts within Australia during the term of the Patent without the licence or authority of the Cross-Claimant:

(a) manufacturing in Australia, or importing into Australia, Levamox Duo;

(b) selling, supplying or otherwise disposing of Levamox Duo in Australia;

(c) offering to manufacture, sell, supply or otherwise dispose of Levamox Duo in Australia; and

(d) authorising, procuring, inducing or joining in a common design with any other person to engage in any of the acts referred to in sub-paragraphs (a) to (c) above.

5. By 22 October 2025, the Cross-Respondents destroy or deliver up to the Cross-Claimant on oath all Levamox Duo, together with all advertising, promotional and packaging material relating to such products, in the possession, custody, power or control of each Cross-Respondent in Australia.

6. Claims 19, 20 and 21 of the Patent be revoked pursuant to s 138(3) of the Patents Act 1990 (Cth).

7. There be an inquiry as to damages or an account of profits.

8. The Originating Application otherwise be dismissed.

9. The Respondent/Cross-Claimant file and serve any affidavits and written submissions in relation to costs by 17 October 2025.

10. The Applicant/Cross-Respondents file and serve any affidavits and written submissions in relation to costs by 31 October 2025.

11. The Respondent/Cross-Claimant file and serve any affidavits and written submissions in reply in relation to costs by 14 November 2025.

12. The matter be listed for case management in relation to the question of the assessment of pecuniary remedies on 31 October 2025 at 9.30 am.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Abbey Laboratories Pty Ltd initiated proceedings against Virbac (Australia) Pty Ltd seeking the revocation of certain claims of a patent held by Virbac, on the basis that the claims were neither novel nor involved an inventive step. The patent in question pertains to an anthelmintic formulation for cattle, specifically a pour-on formulation containing a selected levamisole active ingredient and a macrocyclic lactone dissolved in a non-aqueous system that is stable. The formulation is designed to treat various worm species effectively with a single application. Virbac cross-claimed for infringement of its patent by Abbey. The dispute hinges on the comparison of the patent claims against a prior art base that existed before the patent's priority date. The court had to consider expert evidence concerning the development of the anthelmintic product and the common general knowledge attributable to a person skilled in the art.

The matter came before the Federal Court of Australia following Abbey Laboratories Pty Ltd's application for the revocation of certain claims of a patent held by Virbac (Australia) Pty Ltd. Virbac cross-claimed for infringement of its patent by Abbey. The case involved extensive expert evidence and argument on the novelty and inventive step of the patent claims, as well as on the interpretation of the relevant provisions of the Patents Act 1990 (Cth). The court considered the prior art base, the common general knowledge of a person skilled in the art, and the specific task set for the experts in preparing their evidence. The decision also addressed the application of Ferrcom inferences to expert evidence and the requirements for notional claims in patent law.

Evidence

Evidence Before The Court

The first combination anthelmintic product for cattle, Eclipse Pour-On, was developed in around the early 2000s and registered by Ancare in 2003, being an anthelmintic product involving the combination of a macrocyclic lactone (namely abamectin) and levamisole: Agnew 1 at [48]. Levamisole was known to demonstrate excellent efficacy against Cooperia, and companies responded to the development of resistance in the Cooperia species to macrocyclic lactones by developing combination products (both pour-on and injectable) of macrocyclic lactones with levamisole, such as the Eclipse Pour-On, which effectively treated all worm species with a single application method: Agnew 1 at [50]. As at 23 September 2011, the Eclipse Pour-On product was the market leading pour-on on the market, with the Saturn product (also known as Outlaw) being behind it in terms of market share: Dr Agnew at T133.1–18; and see Dr Alawi at T149.10–13.Disputed Expert Evidence In preparing Alawi 2, Dr Alawi was set the Task, in which he was asked to assume that, as at 23 September 2011, a team that he was a part of had been asked to develop a combination product with acceptable shelf-life stability containing a macrocyclic lactone and levamisole for use in relation to cattle, and being a pour-on formulation. Dr Alawi noted that he had not been told which specific macrocyclic lactone the business would like to use, or whether the formulation could contain a combination of one or more macrocyclic lactones plus an anthelmintic from another family (such as triclabendazole) in addition to levamisole: Alawi 2 at [8]. Senior Counsel for Virbac criticised the elements of the Task as being improperly leading and effectively confining the issues to the question of solvent selection. Virbac submitted that Dr Alawi should have been given an open question as to approaches for new or improved products in the market generally, such as: having regard to the existing products on the market, if you were considering launching a new product or an improved product, what steps would you have undertaken? (T52.1–20). I reject that submission. There is, and was at 23 September 2011, a greater preference at pharmaceutical companies and among cattle farmers for pour-on products, followed by injectables and lastly oral products: Agnew 1 at [59]. In light of the fact that the market-leading products at the time were the anthelmintic pour-on products involving the combination of a macrocyclic lactone and levamisole, namely Eclipse and Saturn (or Outlaw), it is likely that the expert evidence would not have differed materially if the question had been posed in the more open-ended way suggested by Virbac. As Dr Agnew said in his unchallenged evidence, if one was seeking as at 23 September 2011 to develop a new product, one would consider the state of the market, the preference for pour-on products in the market generally and the business’s goals, and having regard to the state of the existing products, the simplest way forward to develop a product in this market would be to develop a new pour-on product containing a macrocyclic lactone and levamisole: Agnew 2 at [38]–[39]. Dr Agnew points out that the existing market-leading pour-on product on the market at the time was the combination macrocyclic lactone (abamectin) and levamisole combination product, namely the Eclipse Pour-On, so in his experience it would be unsurprising that the business would look to develop a new macrocyclic lactone/levamisole dual combination pour-on product. Further, the way in which the Task was framed left the choice of the particular macrocyclic lactone and levamisole open. That is particularly significant in terms of the choice between levamisole in its base form and levamisole in its salt form (such as levamisole hydrochloride), which has a direct bearing on the question whether to use water in the solvent system.

Decision

Reasons for decision

In addition to the general reservations which I have already expressed in relation to Ferrcom inferences, there are particular features of contemporary practice concerning expert evidence which point strongly away from such inferences arising. The Federal Court’s Expert Evidence Practice Note (GPN–EXPT) is broadly representative of the practice throughout the Australian States and Territories, providing for conferences of experts and joint expert reports (section 7), concurrent oral evidence (section 8), and a declaration in expert reports that the expert has made all the inquiries which the expert believes are desirable and appropriate and that no matters of significance which the expert regards as relevant have, to the knowledge of the expert, been withheld from the Court (Annexure A, para 3(i)). Those elements are buttressed by clear restrictions on attempts by parties to interfere with the expert’s expression of opinion (section 3), and duties on the part of experts to provide relevant and impartial evidence (section 4). Contemporary practice thus does not leave any effective room for a party tactically to seek to ensure that certain subject matter is avoided by an expert witness engaged by that party, at least in circumstances where that subject matter is dealt with by a competing expert witness. Whatever scope there may once have been for the drawing of a Ferrcom inference in relation to expert witnesses, I regard that now as having been superseded.Conclusion Accordingly, Abbey’s challenge to the claims in the Patent has failed, except in relation to three claims, namely claims 19, 20 and 21. That very limited measure of success can only be described as a pyrrhic victory for Abbey. Abbey is liable for infringing the Patent, and Virbac is entitled to declarations and injunctions accordingly. Abbey should be granted a period of four weeks before the injunctions take effect in order to allow for an orderly wind-down. There will need to be a case management hearing to prepare for a subsequent hearing on pecuniary remedies. I have not yet heard the parties on costs. My preliminary view is that Virbac is entitled to its costs of the proceedings. There may well be an application for special orders as to costs, such as indemnity costs arising from any offers of compromise and lump sum orders. Accordingly, I have set a timetable for affidavits and written submissions on the question of costs, which I anticipate deciding on the papers.

Ratio Decidendi

Legal Principle Established

In determining whether the claims of the patent lacked inventive step, the court examined the prior art base and the common general knowledge attributable to a person skilled in the art. It required the expert witnesses to undertake the task of developing an anthelmintic using their knowledge as at the priority date. The court found that the applicant’s expert evidence did not reflect the position of a person skilled in the art, and that there was an inventive step when comparing other similar patents. Thus, the court concluded that the claims did not lack inventive step.

Regarding the novelty of the claims, the court considered whether a notional set of claims, in valid form, which would be fairly based on the prior art, was necessary. The court found that the language of the Patents Act did not require the court to determine the hypothetical validity of a notional claim. It concluded that the notional claim requirement adds unnecessary complexity which was not intended by the legislature. By comparing the prior art document with the patent in suit, claim by claim, the court found each of the contested claims to be novel.

The court addressed whether it should follow a previous judge's decision based on 'judicial comity' or depart from it. The court determined that the decision should not be based on 'judicial comity' and that there was a compelling reason to depart from the previous decision.

In relation to the Ferrcom inference and its applicability to expert evidence, the court noted that contemporary practice in expert evidence, as evidenced by the Federal Court’s Expert Evidence Practice Note (GPN–EXPT), requires experts to declare that all appropriate inquiries have been made and no matters of significance have been omitted. The court concluded that such practice left no room for a party to tactically ensure that certain subject matter was avoided by an expert witness engaged by that party, particularly where that subject matter was dealt with by a competing expert witness. Thus, the court found that the Ferrcom inference was superseded.

Finally, the court interpreted the requirement for a notional set of claims in patent law, concluding that the language of the Patents Act did not necessitate the determination of the hypothetical validity of a notional claim and that the notional claim requirement adds unnecessary complexity which was not intended by the legislature. The court compared the prior art document with the patent in suit, claim by claim, and found each of the contested claims to be novel.